Telomir-1 kills aggressive human leukemia cells in vitro; expands oncology profile into blood cancers

Telomir Pharmaceuticals, Inc.

Telomir-1 produced dose-dependent reduction in viability of human HL60 leukemia cells (aggressive AML model).
Leukemia cells depend on intracellular iron; Telomir-1 lowers intracellular Fe²⁺ more potently than DFO.
Prior research shows Telomir-1 reduces abnormal DNA methylation of tumor-suppressor genes and inhibits KDM histone demethylases.
Findings add to previously reported activity against triple-negative breast, pancreatic, and prostate cancer models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.